Enliven Therapeutics (ELVN) Non-cash Items (2019 - 2025)

Enliven Therapeutics has disclosed Non-cash Items across 7 years of filings, most recently posting $5.0 million for Q4 2025.

• Non-cash Items for Q4 2025 came in at $5.0 million, down 92.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.0 million (down 92.76% YoY), and the FY2025 annual result was $5.0 million, down 92.76% from the prior year.
• Non-cash Items came in at $5.0 million for Q4 2025 at Enliven Therapeutics, down from $69.2 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $69.2 million in Q4 2024 to a low of $9000.0 in Q2 2022.
• The 5-year median for Non-cash Items is $3.8 million (2021), against an average of $11.8 million.
• Across the five-year window, Non-cash Items slumped 99.77% in 2022 and jumped 2889.28% in 2023, its largest moves.
• Enliven Therapeutics' Non-cash Items stood at $9.7 million in 2021, then plunged by 87.64% to $1.2 million in 2022, then surged by 2889.28% to $35.7 million in 2023, then surged by 93.86% to $69.2 million in 2024, then slumped by 92.76% to $5.0 million in 2025.
• The last three Non-cash Items figures came in at $5.0 million (Q4 2025), $69.2 million (Q4 2024), and $35.7 million (Q4 2023), per Business Quant data.